This study will test the effect of a 6-session occupational therapy program delivered via online video visits called telerehabilitation. The study will involve stroke survivors who have had a stroke at least 1 month ago and have weakness of one arm or hand from the stroke. The occupational therapy sessions will take place while the stroke survivor is located in his/her own home. The stroke survivor will interact with a licensed, experienced occupational therapist via a video call on the stroke survivor's own phone, tablet or laptop. The goal of the telerehabilitation program will be to improve the stroke survivor's abilities to be more engaged in meaningful life activities. The entire study will occur over a 6-week period.

This research study evaluates the effects of an investigational medication, NAC, in individuals with Bipolar Disorder and Alcohol Use Disorder. Participants in the study will be assigned to one of two medication conditions and will take either NAC or a matched placebo. Study medication will be taken for 28 days. There will be 5 study visits, with 3 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.

The goal of this study is to determine which brain health interventions are most beneficial for different people with memory concerns. Participants will complete two at-home interventions that are paired with transcutaneous auricular vagus nerve stimulation (taVNS). The first is computerized brain games, and the other is mindfulness training (MIND). Participants will be randomly assigned to complete one program first and then switch to the other program.

This research study aims to better understand patient experiences with accessing genetic counseling services for hypermobile Ehlers-Danlos syndrome (hEDS). The study will include a review of MUSC medical records to better understand referral patterns to genetic counseling services among patients with hEDS. Patients with hEDS will also be asked to complete a survey about their experiences with accessing genetic counseling services. Healthcare providers will be asked to complete a separate survey about their experiences referring patients with hEDS to genetic counseling services and potential factors that may influence the referral process. The surveys will take approximately 10-15 minutes to complete.

There are minimal risks to participants but may include possible loss of confidentiality or discomfort when answering questions related to healthcare experiences. There is no direct benefit to participants, but the information provided may help improve access to genetic counseling services for future patients with hEDS. Participation in the surveys is completely voluntary.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 2. Administered upon wakening and a second time 3-5 hours later, 3 different doses will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

The 12 week study is designed to assess the efficacy and safety of the twice daily ALKS2680, in narcolepsy Type 1. Administered upon wakening and a second time 5-7 hours later, 2 different doses (6mg and 10mg) will be compared to a placebo. The effects of ALKS2680 on excessive daytime sleepiness and sleep quality will be examined during overnight and daytime sleep studies.

This study is for patients diagnosed with a solid tumor malignancy of any stage and identified as high risk (having a 6-month mortality estimate). The study is evaluating A-PACT (algorithm-Enables Patients Activated in Cancer Care through Teams). The subjects will be randomized (like flipping a count) to determine if they will receive A-PACT with usual care or usual care alone. The primary purpose of this study is to determine if the A-PACT Program reduces unplanned hospital visits and improves communication between patients and their health care team. Participants in this study can expect to be in this study for 12 months or their withdrawal of consent.

A 95-week study comparing the efficacy and safety of a specific dose of a trial product named zenagamtide versus two different doses of semaglutide, administered once weekly via injection along with a reduced-calorie diet and increased physical activity on weight management in participants with obesity.

This study aims to learn how adolescents and young adults who received a liver transplant as children think about their transplant and prepare to manage their healthcare as they get older. Participants will complete questionnaires and may take part in an interview about their experiences, feelings, and healthcare responsibilities. The study will explore how young people view their transplant, how it fits into their sense of self, and how these factors relate to their readiness for adult healthcare. Information from this study will help researchers better understand the needs of young liver transplant recipients and guide the development of future support programs.

This study is for people with advanced head and neck cancer who cannot receive cisplatin. The purpose of this study is to compare treating head and neck cancer with radiation plus cetuximab versus radiation plus chemotherapy (carboplain and paclitaxel). Carboplatin, paclitaxel, and cetuximab are approved by the FDA to treat head and neck cancer.

If you agree to take part, we expect that your participation in this study may last up to 3 years. This includes visits to the clinic after you finish all study treatments. These follow-up visits will take place about every 2 months during the 1st year and about every 4 months thereafter.

Risks may include nausea, vomiting, headache, feeling tired, loss of appetite, and hair loss. Participants may or may not receive a direct benefit from participating in this trial, however, information learned from the trial may help other people in the future.